Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment

FARMINGTON, Conn., May 17, 2013 /PRNewswire-iReach/ -- The escalation of new biological drugs, including antibodies and recombinant proteins, is placing renewed emphasis on alternate delivery technologies. Alternate delivery technologies are on the rise as a number of factors are converging to create both risk and opportunity for pharmaceutical makers and their delivery device partners. These include new classes of drugs for previously refractory conditions, the growing trend toward self-administration for chronic diseases, shifting patient demographics in industrial countries, caregiver safety legislation, and continued pressure to control healthcare costs.

(Photo: http://photos.prnewswire.com/prnh/20130517/CG15876)

These factors are giving rise to a new generation of sophisticated, application-specific injection, inhalation and transdermal drug products designed to satisfy caregiver and patient preferences while addressing managed care initiatives and the formulation limitations of new classes of therapeutic drugs. Because of their ability to safely and reliably satisfy treatment protocols and compliance goals, non-oral drug delivery products will have a significant impact on the future of drug self-administration.

The new Drug Self-Administration to 2018: Drug Products, Indications, Markets and Forecasts report is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the drug delivery sector.

Request a free sample from Global Information's market research portal to learn more or easily order your copy online here.

For more recently released reports from Greystone Research Associates please visit the following links:

Transdermal Drug Patches to 2018: Products, Indications, Markets and Forecasts

Published March, 2013

Injectable Drug Delivery to 2018: Drugs, Devices, Targets, Therapeutics and Forecasts

Published March, 2013

Autoinjectors to 2018: Devices, Therapeutics, Market, Strategies and Prospects

Published March, 2013

About Global Information Inc. Global Information (GII) (http://www.giiresearch.com) is an information service company partnering with over 400 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 30 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.

About Greystone Research Associates As life science consultants, Greystone Research Associates focuses on one industry and one objective - providing management guidance in an increasingly dynamic medical technology marketplace. The value Greystone Research Associates provides to their clients and subscribers is best illustrated by their ability to consistently provide strategic direction and market knowledge that contributes to their tactical and strategic decision process. Greystone Research Associates delivers their knowledge franchise through concise market appraisals, company analysis, and technology reports. Their publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge necessary to refine and execute their marketing plans and achieve their financial targets.

Media Contact:  Joe Malley Global Information, Inc., 1-860-674-8796, [email protected]

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Global Information, Inc.